Vaccine MN confer protective innate and adaptive immunity.

Slides:

Advertisements

Similar presentations

Identification of combination treatment–responsive dysfunctional tumor-infiltrating CD8+ T cell population. Identification of combination treatment–responsive.

Advertisements

Fibroblast activation in WT and NFATc2-deficient mice.

In vivo responses of AMLMLL to ATRi.

Immunologic responses after the MN-mediated cancer immunotherapy.

IFN-γ antagonizes TGF-β in vivo.

Cytotoxicity of MSP samples to normal and cancer cell lines.

IFN-γ activates the fibrinolytic system.

Fig. 7 Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors. Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors.

Neutrophil antifungal response in CCR2-depleted mice is rescued by adoptive transfer of CCR2+ monocytes or by treatment with recombinant IFNs. Neutrophil.

Both type I and III IFNR signaling are essential for protection against IA. Both type I and III IFNR signaling are essential for protection against IA.

NFATc2-deficient mice do not eliminate skin C. albicans infections.

Antitumor effect of local cancer immunotherapy treatment toward distant B16F10 tumors. Antitumor effect of local cancer immunotherapy treatment toward.

Specific depletion of CD4-DTR–derived CD4 T cells.

The TGF-β pathway is activated in the skin after C

Fig. 5 Local gel scaffold for T cell memory response.

Mice with neutrophil-specific deletion of IFNLR1 or STAT1 succumb to IA. Mice with neutrophil-specific deletion of IFNLR1 or STAT1 succumb to IA. Conditional.

Ex vivo testing of the soft robotic devices.

Fig. 3 Agonists of innate immunity are effective only when released locally from the hydrogel. Agonists of innate immunity are effective only when released.

Arp2/3-mediated formation of nuclear actin networks is essential for CD4+ T cell effector functions. Arp2/3-mediated formation of nuclear actin networks.

Platelets are required for hFcγRIIA-induced anaphylaxis.

Tfr cell–derived IL-10 is important for B cell differentiation and the GC response. Tfr cell–derived IL-10 is important for B cell differentiation and.

Characterization of the light-responsive transdermal MNs.

IFN-γ antagonizes TGF-β in vivo.

Immune cell recruitment after the NIR-boosted and MN-mediated cancer immunotherapy. Immune cell recruitment after the NIR-boosted and MN-mediated cancer.

Antitumor effect of local cancer immunotherapy treatment in various tumor models. Antitumor effect of local cancer immunotherapy treatment in various tumor.

Cell viability tests. Cell viability tests. SEM images of (A) MC3T3-E1 cells and (B) MSCs on days 1, 3, and 5 of culture. (C) Survival rates of MC3T3-E1.

Administration of necroptosis-targeting AAVs in conjunction within vivo promotes durable tumor clearance. Administration of necroptosis-targeting AAVs.

Immune-mediated tumor control by necroptotic cells requires NF-κB activation within dying cells but not MLKL-mediated cell lysis and DAMP release. Immune-mediated.

Tumor control by necroptotic cells requires BATF3+cDC1 and CD8+leukocytes. Tumor control by necroptotic cells requires BATF3+cDC1 and CD8+leukocytes. (A)

Experimental results for tremor reduction.

Fig. 3 M7824 inhibits tumor growth and metastasis and provides long-term antitumor immunity. M7824 inhibits tumor growth and metastasis and provides long-term.

Fig. 5 A competent Fc is required for the antitumor immune response.

Cardiomyocytes cultured on microgroove-patterned structural color hydrogel films. Cardiomyocytes cultured on microgroove-patterned structural color hydrogel.

Microrobots with different cell-carrying capacities under different grid lengths (lg) and burr lengths (lb). Microrobots with different cell-carrying capacities.

IFN-γ activates the fibrinolytic system.

Genetic EGFR ablation in K-RAS–mutated lung AC reduces tumor growth

Innate immune and fibrinolytic systems cooperate also during bacterial infections. Innate immune and fibrinolytic systems cooperate also during bacterial.

Fig. 3 NK cells are enriched in ICB-sensitive tumors in mouse models and patients and are required for response. NK cells are enriched in ICB-sensitive.

Fig. 1. CAR4 and CAR8 cells demonstrate in vitro and in vivo antileukemic efficacy. CAR4 and CAR8 cells demonstrate in vitro and in vivo antileukemic efficacy.

CD25 surface expression and TCR signal strength predict T helper differentiation and memory potential of early effector T cells in vivo. CD25 surface expression.

Fig. 4 Rational therapeutic modulation of the tumor microenvironment sensitizes tumors to ICB. Rational therapeutic modulation of the tumor microenvironment.

Fig. 2 In situ vaccination of CpG in combination with anti-OX40 antibody cures established local and distant tumors. In situ vaccination of CpG in combination.

Tfr cells respond better to immunization with self-antigens than with foreign antigens. Tfr cells respond better to immunization with self-antigens than.

Dox administration was required for Tet-CD19CAR T cells to show a suppressive function against a CD19+ tumor in vivo. Dox administration was required for.

In situ concurrent removal of MRSA bacteria and MRSA-secreting PFTs by RBC-PL-robots. In situ concurrent removal of MRSA bacteria and MRSA-secreting PFTs.

S-Affs colocalize with SUMO in mammalian cells.

Type I and III IFNR expression on hematopoietic cells is required for protection against IA. Type I and III IFNR expression on hematopoietic cells is required.

In vivo assessment of synergistic activity of MV-CEA and RT in a U87 s

Galloping-like gait with the design of a two-legged robot.

AEGIS autonomous targeting process.

coTCRcys-transduced T cells control tumor growth in vivo.

Fig. 2 Extended local release of agonists of innate immunity prevents tumor recurrence and eliminates distal metastases. Extended local release of agonists.

Fig. 3 Local Maraba treatment of TNBC tumors provides long-term systemic protection. Local Maraba treatment of TNBC tumors provides long-term systemic.

CD4+ memory T cells derived from either CD25hi or CD25lo effector cells respond robustly to secondary challenge. CD4+ memory T cells derived from either.

Functional characterization of multidonor class antibodies.

Neutrophil antifungal response in CCR2-depleted mice is rescued by adoptive transfer of CCR2+ monocytes or by treatment with recombinant IFNs. Neutrophil.

Pharmacological targeting of CDs promotes response to KRASG12C inhibition in vivo. Pharmacological targeting of CDs promotes response to KRASG12C inhibition.

Chronic Treg reduction results in dermal fibrosis.

Tregs preferentially regulate TH2 cytokines in skin.

Fig. 6 Antitumor effect on tumor growth and pulmonary metastasis of CSSD-9 in vivo. Antitumor effect on tumor growth and pulmonary metastasis of CSSD-9.

Tumor protection induced by therapeutic PLG vaccination in combination with blockade antibodies. Tumor protection induced by therapeutic PLG vaccination.

In vivo prophylactic and therapeutic efficacy of C12G6 in mice

Fig. 4 In vivo evaluation of insulin complex for type 1 diabetic mice treatment. In vivo evaluation of insulin complex for type 1 diabetic mice treatment.

AV3 potentiates the effect of gemcitabine in the PDX model in mice

Fig. 5 In vivo autologous self-targeting efficacy of DR-KO tumor cells co-engineered with a secretable DRL and a suicide system. In vivo autologous self-targeting.

Fibroblast activation in WT and NFATc2-deficient mice.

Fig. 6. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex vivo. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex.

Fig. 3 Superiority of BAFF-R versus CD19-CAR T cells in a Burkitt lymphoma model is not due to greater tumor antigen density. Superiority of BAFF-R versus.

PD and efficacy of AZD4785 in a KRAS wild-type lung cancer PDX model

CCR6 is dispensable for expansion of innate TCRαβ+ cells in oral candidiasis. CCR6 is dispensable for expansion of innate TCRαβ+ cells in oral candidiasis.

Presentation transcript:

Vaccine MN confer protective innate and adaptive immunity. Vaccine MN confer protective innate and adaptive immunity. (A) Schematic illustration of MN cancer immunotherapy. (B) Characterization of the MNs after insertion. (i) Photo of mouse dorsal skin (the area within the red line) that was treated transdermally with one MN patch and (ii) fluorescence signals of Cy5.5-labeled MN patch over time. (C) Surface temperature changes of individual animal after MN insertion into the skin measured by an infrared thermal camera. (D) Schematic representation of the B16F10 vaccine tumor model. (E) Average tumor volumes in treated mice after tumor challenge. (F) Kaplan-Meier survival curves for treated and control mice. Data points represent mean ± SD (n = 8). Error bars indicate SD. Statistical significance was calculated by Student’s test and log-rank test (**P < 0.01; ***P < 0.001). (G) In vivo bioluminescence imaging of the B16F10 melanoma in different experimental groups and at different time points after tumor challenge. Three representative mice per treatment group are shown. The tumor growth in (E) to (G) was measured 10 days after tumor cell inoculation. Yanqi Ye et al. Sci. Immunol. 2017;2:eaan5692 Copyright © 2017 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works